U.S. Health Care REITs Stock News

NasdaqGS:EMBC
NasdaqGS:EMBCMedical Equipment

Embecta (EMBC) Is Down 60.7% After Dividend Cut And Buyback Shift - What's Changed

In early May 2026, Embecta Corp. reported a year-over-year drop in quarterly sales to US$221.8 million and swung from a net income of US$23.5 million to a net loss of US$4.1 million, while also slashing its quarterly dividend to US$0.01 per share and authorizing a three-year, US$100 million share repurchase program. The combination of weaker Q2 results, lowered full-year guidance, a sharply reduced dividend, and the planned Owen Mumford acquisition highlights how Embecta is reshaping its...
NYSE:GOLD
NYSE:GOLDRetail Distributors

Gold.com (GOLD) Q3 Earnings Surge While Ultra Thin Margins Challenge Bullish Narratives

Gold.com (GOLD) just posted Q3 2026 results with revenue of about US$10.4b and net income of US$59.5m, equal to EPS of US$2.17, against a backdrop of 112.2% earnings growth over the past year and low net margins of around 0.3%. The company has seen quarterly revenue move from US$3.0b in Q3 2025 to US$10.4b in Q3 2026, while EPS shifted from a loss of US$0.36 to a profit of US$2.17 over the same periods, highlighting a combination of earnings momentum and thin margins for investors. See our...
NasdaqCM:VRDN
NasdaqCM:VRDNBiotechs

Reassessing Viridian Therapeutics (VRDN) After Volatile Share Price Swings

If you are wondering whether Viridian Therapeutics at around US$16.97 is priced for opportunity or risk, the key question is what that tag really says about the business. The stock has recently shown sharp moves, with returns of 25.9% over 7 days and 21.6% over 30 days, while year to date it is down 44.7% and up 32.8% over the past year. This mix of recent gains and earlier weakness has put valuation back in focus as investors reassess what they are willing to pay for Viridian Therapeutics...